Ciloa is dedicated to the production of fully native membrane proteins on exosomes. Based in Montpellier, France, the company was created in 2011 by Robert MAMOUN and Bernadette TRENTIN. The company is a spin-off of the CNRS and the University of Montpellier.
It has exclusive proprietary technology for developing recombinant exosomes in therapeutic and preventive applications.
Ciloa exosomes offer a disruptive way to develop a new generation of therapeutic and preventive vaccines, monoclonal antibodies, immunotherapies, and therapeutic vectors carrying drug cargo. Its unique technology allows to drug undruggable targets.
Based on 2 international families of patents under worldwide exclusive license, its technology has full freedom to operate.